January 16, 2025

New Publication from AbbVie and Sciomics: Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays

New Publication from AbbVie and Sciomics: Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays

Kenzelmann A, Boch C, Schmidt R, Richter M, Schulz M. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024 Dec 9;12(12):2794. doi: 10.3390/biomedicines12122794. PMID: 39767701; PMCID: PMC11673003.

Abstract

Background/objectives: Neurodegenerative diseases are a major cause of morbidity and mortality worldwide, and their public health burden continues to increase. There is an urgent need to develop reliable and sensitive biomarkers to aid the timely diagnosis, disease progression monitoring, and therapeutic development for neurodegenerative disorders. Proteomic screening strategies, including antibody microarrays, are a powerful tool for biomarker discovery, but their findings should be confirmed using quantitative assays. The current study explored the feasibility of combining an exploratory proteomic strategy and confirmatory ligand-binding assays to screen for and validate biomarker candidates for neurodegenerative disorders.

Methods: It analyzed cerebrospinal fluid (CSF) and plasma samples from patients with Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis and healthy controls using an exploratory antibody microarray and validatory ligand-binding assays.

Results: The screening antibody microarray identified differentially expressed proteins between patients with neurodegenerative diseases and healthy controls, including cluster of differentiation 14 (CD14), osteopontin, and vascular endothelial growth factor 165b. Quantitative ligand-binding assays confirmed that CD14 levels were elevated in CSF of patients with Alzheimer’s disease (p = 0.0177), whereas osteopontin levels were increased in CSF of patients with Parkinson’s disease (p = 0.0346).

Conclusions: The current study demonstrated the potential utility of combining an exploratory proteomic approach and quantitative ligand-binding assays to identify biomarker candidates for neurodegenerative disorders. To further validate and expand these findings, large-scale analyses using well-characterized samples should be conducted.

Our latest News

discover more
All Experimentica sites are now CIR-accredited

All Experimentica sites are now CIR-accredited

Experimentica’s sites have gained CIR accreditation for 2026-2028, enabling eligible French companies to benefit from CIR-covered preclinical ophthalmic research services. Experimentica’s Kuopio and Vilnius sites are now both CIR-accredited for 2026–2028. Our Kuopio site has held the accreditation since 2020, and with the addition of our Vilnius site, French biotech and pharmaceutical companies can access […]

Helmholtz Doctoral Award for Mariam Amghar

Helmholtz Doctoral Award for Mariam Amghar

In her doctoral thesis at the German Cancer Research Center (DKFZ), Mariam Amghar investigated why some prostate cancer patients respond to radioactive drugs while others do not. Her findings may help tailor treatment more effectively to individual patients in the future. Mariam Amghar has been awarded the Helmholtz Doctoral Prize in the “Health” category. At […]

Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award

Mirco Friedrich Receives the Peter and Traudl Engelhorn Foundation Award

Mirco Julian Friedrich, a physician and cancer researcher at the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Research Institute, and Heidelberg University Hospital (UKHD), is being honored for his outstanding research on the aging immune system and the immune response to blood cancer. Mirco Friedrich leads a junior research group at the DKFZ […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp